Assessment of growth potential by MIB‐1 immunohistochemistry in ameloblastic fibroma and related lesions of the jaws compared with ameloblastic fibrosarcoma

Abstract

Sano K, Yoshida S, Ninomiya H, Ikeda H, Ueno K, Sekine J, Iwamoto H, Uehara M, Inokuchi T: Assessment of growth potential by MIB‐1 immunohistochemistry in ameloblastic fibroma and related lesions of the jaws compared with ameloblastic fibrosarcoma. J Oral Pathol Med 1998; 27: 59–63. © Munksgaard, 1998. Specimens from two ameloblastic fibromas (including one recurrent case), two ameloblastic fibro‐odontomas, and one ameloblastic fibrosarcoma were subjected to investigation by MIB‐1 immunohistochemistry in order to elucidate the growth potential of these tumors. MIB‐1 labeling indices in the epithelial component of these tumors ranged from 2.9 to 7.5%, whereas those in the mesenchymal component ranged from 1.5 to 13.5%. Of these, labeling indices in the mesenchymal component of the recurrent ameloblastic fibroma and ameloblastic fibrosarcoma were quite high. These findings suggest that evaluation of growth potential in ameloblastic fibroma and related lesions could be of help in understanding tumor aggressiveness and in selecting appropriate surgical procedures.

Ameloblastic Fibrosarcoma: A Case Report and Literature Review

“…When Ki-67 was quantified, positivity rates ranged from 13.5% to 60.0% for the malignant mesenchymal component. Although no established cutoff value for Ki-67 positivity has been reported in the literature, the present case is within the interval of Ki-67 expressed in malignant lesions (~20.0%), suggesting that proliferative factors, in association with histopathological features, may be useful markers for the identification of malignant cases (4,5,69,79,88,89,113).…”

“…The search strategy resulted in the identification of 119 cases in 88 articles (4-6,9-13, 113 disease; the remaining patients (6/8) had no evidence of disease at the last recorded appointment. Only two cases were diagnosed with AFDS, (13,45) and both involved the posterior mandibles of non-white male patients in the third decade of life (mean, 26±1.4 years).…”

“…Immunohistochemical studies may facilitate diagnosis of these lesions, given that Ki-67, PCNA and p53 were found expressed at higher levels within the sarcomatous component of the AFS, whereas they are absent or expressed at lower levels in AF (5,12,62,69,79,89,101,113,123). Results obtained from several papers (4,5,69,79,82,88,89,113) revealed that Ki-67 was overexpressed (highly diffuse positivity) in the malignant mesenchymal portion of AFS, compared with AF.…”

“…Results obtained from several papers (4,5,69,79,82,88,89,113) revealed that Ki-67 was overexpressed (highly diffuse positivity) in the malignant mesenchymal portion of AFS, compared with AF. When Ki-67 was quantified, positivity rates ranged from 13.5% to 60.0% for the malignant mesenchymal component.…”

Controversial Odontogenic Hamartomas- Review on Their Pathogenesis and Histopathology

“…There is usually a juxta epithelial hyalinization around those islands signifying the process of epithelial mesenchymal interaction [17] . Immunohistochemical markers like proliferating cell nuclear antigen (PCNA) and MIB-1 has been studied where it was found that MIB-1 has been expressed in the mesenchymal component suggesting the higher labeling indices in the Mesenchymal component rather than the epithelial component [18,19] . The role of these markers helped in understanding the growth and aggressive potential of the tumours.…”